Clinical Trial Update: Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 study of GP40141 in immune thrombocytopenia is ongoing, with a focus on efficacy, safety, and immunogenicity; current status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• GP40141

Snippet

Sponsor: Geropharm | Conditions: Drug Effect, Safety Issues | Phase 3 | Status: ACTIVE_NOT_RECRUITING